January 4, 2018 03:02 AM EST

Novartis backs eye drop maker in $20M round, meds to fill gap left by Eylea/Lucentis

Brittany Meiling

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Biogen taps City Therapeutics in RNAi deal worth up to $1B

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation